目的:应用网络药理学分析具有抗炎功效的调胃和中汤治疗慢性胃炎的作用机制。方法:使用中医药系统药理学数据库与分析平台(TCMSP)检索调胃和中汤中单味药活性成分与作用靶点,在相关数据库中检索慢性胃炎的疾病靶点。将预测的药物与疾病...目的:应用网络药理学分析具有抗炎功效的调胃和中汤治疗慢性胃炎的作用机制。方法:使用中医药系统药理学数据库与分析平台(TCMSP)检索调胃和中汤中单味药活性成分与作用靶点,在相关数据库中检索慢性胃炎的疾病靶点。将预测的药物与疾病交集靶点导入STRING数据库进行分析并搭建蛋白互作网络(PPI)。基于Metascape数据库进行GO功能与KEGG通路富集分析,并绘制相应结果图,探究其作用机制。结果:检索后共获得活性成分对应靶点332个,其中作用于慢性胃炎的交集靶点有112个;蛋白互作网络关键靶点主要为AKT1、IL-6、TNF、TP53、IL-Iβ、JUN等。GO富集分析得到富集的生物过程集中在对外来生物刺激、氧化应激及激素的反应,对细胞增殖、迁移的调节,对凋亡信号通路的调控等方面;KEGG通路富集分析结果显示,调胃和中汤可能通过介导AGE-RAGE、PI3K-AKT、JAK-STAT和NF-κB等信号通路发挥疗效。结论:该研究结果初步揭示了调胃和中汤通过多成分、多靶点、多通路治疗慢性胃炎,但尚有不足之处,需要后期实验研究进一步验证。Objective: The mechanism of Tiaoweihezhong Decoction with anti-inflammatory effect on chronic gastritis was studied by using network pharmacology. Methods: The TCMSP platform was used to search the single ingredient and target of Tiaoweihezhong Decoction, and the disease target of chronic gastritis was searched in databases. The predicted intersection targets of drugs and diseases were imported into the STRING database for analysis and the protein interaction network was constructed. The enrichment analysis of GO function and KEGG pathway was carried out based on Metascape database, and corresponding result diagrams were drawn according to the results. The “target-pathway” network was constructed by Cytoscape 3.7.2 to explore its mechanism. Results: A total of 332 targets corresponding to active ingredients were obtained, of which 112 were intersections for chronic gastritis;The key targets of the protein interaction network were AKT1, IL-6, TNF, TP53, IL-Iβ, JUN, etc. The GO pathway enrichment analysis showed that the enriched biological processes included the response to foreign biological stimuli, oxidative stress and hormones, the regulation of cell proliferation and migration, and the regulation of apoptosis signaling pathways. The results of KEGG pathway enrichment analysis showed that Tiaoweihezhong Decoction may exert therapeutic effect by acting on AGE-RAGE, PI3K-Akt, JAK-STAT and NF-κB signaling pathways, etc. Conclusion: The results of this study preliminarily revealed that Tiaoweihezhong Decoction can treat chronic gastritis through multi-component, multi-target and multi-pathway. But there are still many shortcomings, which need to be verified by later experimental studies.展开更多
目的探索晚期胃和胃-食管结合部癌(gastric cancer or gastroesophageal junction cancer,GC/GEJC)患者化疗联合免疫治疗的临床特点及预期生存。方法收集解放军总医院第一医学中心肿瘤内科2015年5月-2019年5月治疗的晚期GC/GEJC患者。3...目的探索晚期胃和胃-食管结合部癌(gastric cancer or gastroesophageal junction cancer,GC/GEJC)患者化疗联合免疫治疗的临床特点及预期生存。方法收集解放军总医院第一医学中心肿瘤内科2015年5月-2019年5月治疗的晚期GC/GEJC患者。37例化疗患者为化疗组,采用以氟尿嘧啶(5-FU/卡培他滨/替吉奥)联合铂类或紫杉类的双药化疗,34例接受化疗联合免疫检查点(PD-1)抑制剂纳武单抗(Nivolumab)或派姆单抗(Pembrolizumab)的患者为联合组。结果联合组和化疗组中位无进展生存期(progression-free survival,PFS)分别为3.93个月(95%CI:1.56~6.30)和4.97个月(95%CI:3.36~6.58)(P=0.242),中位总生存期(overall survivsal,OS)分别为14.37个月(95%CI:8.17~20.57)和12.52个月(95%CI:9.82~15.22)(P=0.101),客观缓解率为23.5%和18.9%(P=0.634),疾病控制率为79.4%和75.7%(P=0.707)。两组药物临床安全性良好,不良反应均以Ⅰ~Ⅱ级为主。结论化疗联合免疫治疗对于晚期GC/GEJC患者有一定的临床获益,需进一步探索治疗策略及筛选免疫治疗的优势人群。展开更多
文摘目的:应用网络药理学分析具有抗炎功效的调胃和中汤治疗慢性胃炎的作用机制。方法:使用中医药系统药理学数据库与分析平台(TCMSP)检索调胃和中汤中单味药活性成分与作用靶点,在相关数据库中检索慢性胃炎的疾病靶点。将预测的药物与疾病交集靶点导入STRING数据库进行分析并搭建蛋白互作网络(PPI)。基于Metascape数据库进行GO功能与KEGG通路富集分析,并绘制相应结果图,探究其作用机制。结果:检索后共获得活性成分对应靶点332个,其中作用于慢性胃炎的交集靶点有112个;蛋白互作网络关键靶点主要为AKT1、IL-6、TNF、TP53、IL-Iβ、JUN等。GO富集分析得到富集的生物过程集中在对外来生物刺激、氧化应激及激素的反应,对细胞增殖、迁移的调节,对凋亡信号通路的调控等方面;KEGG通路富集分析结果显示,调胃和中汤可能通过介导AGE-RAGE、PI3K-AKT、JAK-STAT和NF-κB等信号通路发挥疗效。结论:该研究结果初步揭示了调胃和中汤通过多成分、多靶点、多通路治疗慢性胃炎,但尚有不足之处,需要后期实验研究进一步验证。Objective: The mechanism of Tiaoweihezhong Decoction with anti-inflammatory effect on chronic gastritis was studied by using network pharmacology. Methods: The TCMSP platform was used to search the single ingredient and target of Tiaoweihezhong Decoction, and the disease target of chronic gastritis was searched in databases. The predicted intersection targets of drugs and diseases were imported into the STRING database for analysis and the protein interaction network was constructed. The enrichment analysis of GO function and KEGG pathway was carried out based on Metascape database, and corresponding result diagrams were drawn according to the results. The “target-pathway” network was constructed by Cytoscape 3.7.2 to explore its mechanism. Results: A total of 332 targets corresponding to active ingredients were obtained, of which 112 were intersections for chronic gastritis;The key targets of the protein interaction network were AKT1, IL-6, TNF, TP53, IL-Iβ, JUN, etc. The GO pathway enrichment analysis showed that the enriched biological processes included the response to foreign biological stimuli, oxidative stress and hormones, the regulation of cell proliferation and migration, and the regulation of apoptosis signaling pathways. The results of KEGG pathway enrichment analysis showed that Tiaoweihezhong Decoction may exert therapeutic effect by acting on AGE-RAGE, PI3K-Akt, JAK-STAT and NF-κB signaling pathways, etc. Conclusion: The results of this study preliminarily revealed that Tiaoweihezhong Decoction can treat chronic gastritis through multi-component, multi-target and multi-pathway. But there are still many shortcomings, which need to be verified by later experimental studies.
文摘目的探索晚期胃和胃-食管结合部癌(gastric cancer or gastroesophageal junction cancer,GC/GEJC)患者化疗联合免疫治疗的临床特点及预期生存。方法收集解放军总医院第一医学中心肿瘤内科2015年5月-2019年5月治疗的晚期GC/GEJC患者。37例化疗患者为化疗组,采用以氟尿嘧啶(5-FU/卡培他滨/替吉奥)联合铂类或紫杉类的双药化疗,34例接受化疗联合免疫检查点(PD-1)抑制剂纳武单抗(Nivolumab)或派姆单抗(Pembrolizumab)的患者为联合组。结果联合组和化疗组中位无进展生存期(progression-free survival,PFS)分别为3.93个月(95%CI:1.56~6.30)和4.97个月(95%CI:3.36~6.58)(P=0.242),中位总生存期(overall survivsal,OS)分别为14.37个月(95%CI:8.17~20.57)和12.52个月(95%CI:9.82~15.22)(P=0.101),客观缓解率为23.5%和18.9%(P=0.634),疾病控制率为79.4%和75.7%(P=0.707)。两组药物临床安全性良好,不良反应均以Ⅰ~Ⅱ级为主。结论化疗联合免疫治疗对于晚期GC/GEJC患者有一定的临床获益,需进一步探索治疗策略及筛选免疫治疗的优势人群。
